DJIA 18,132.70 -81.72 -0.45%
NASDAQ 4,963.53 -24.36 -0.49%
S&P 500 2,104.50 -6.24 -0.30%
market minute promo


company name or ticker
Company Photos
(Click to zoom)

Jim Cramer's Top Stock Picks: TWTR BMY NUE WFC

'Mad Money' Lightning Round: Take Nucor Over United States Steel

AstraZeneca Might Need More Than Buzzwords To Bridge The Gap

3 Medical Advancements You May Be Missing Out On

Motley Fool healthcare analysts highlight medical innovations that could prove to be profit friendly.

Which Biotech Stock Should Pfizer, Inc. Buy?

Motley Fool contributors offer up three potential acquisition targets for Pfizer.

3 Drugs That Could Become Blockbusters in 2015

Pharmacyclics, Celgene Corp., Bristol-Myers Squibb, and Pfizer could see sales of new drugs eclipse $1 billion this year.

3 Blockbuster Drugs That May Be Obsolete in 5 Years

Motley Fool experts highlight three blockbuster-selling therapies that could fall by the wayside in the next five years.

Can You Guess the Stock Putting Gilead Sciences to Shame? (Hint: It's Not AbbVie)

Pharmacyclics and Johnson & Johnson's CLL drug Imbruvica is outselling Gilead Sciences Zydelig.

AstraZeneca Lags Q4 Earnings, to Boost Respiratory Portfolio - Analyst Blog

Merck Posts Disappointing Numbers As Experimental Hepatitis C Treatment Loses Breakthrough Designati

Merck Posts Disappointing Numbers As Experimental Hepatitis C Treatment Loses Breakthrough Designation
See More Articles...